Interstitial Lung Disease (ILD)
Interstitial lung disease (ILD) includes many different types of chronic lung conditions that make it hard to breathe—typically due to inflammation and scarring of the lung tissue. If you're living with ILD, you can get help from some of the world's leading experts at Cedars-Sinai, which is ranked among the nation's top hospitals for lung care by U.S. News & World Report. Using the latest advancements in the diagnosis and treatment of ILD, dedicated care teams will work alongside you to help you understand and manage your symptoms—so you can breathe better and get back to the activities you enjoy.
Pioneering Treatment for IPF
Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD, affecting as many as 100,000 people in the U.S. Idiopathic means there's no known cause of the condition. IPF can progress quickly, which makes treatment challenging. Doctors at Cedars-Sinai were involved in testing pirfenidone and nintedanib, the only two U.S. Food and Drug Administration-approved antifibrotic medications shown to slow the progression of IPF.
Early, accurate detection is vital to managing your symptoms and slowing disease progression. Research conducted at Cedars-Sinai has led to significant strides in diagnosing lung illnesses more quickly. Major developments include pinpointing genetic links and establishing a tissue bank for ongoing research.
Cedars-Sinai is also testing a first-of-its-kind scanner that creates live, 3D images of lung tissue and can measure lung function more precisely using radiographic images. These images will eventually help doctors detect lung disease earlier than ever before, so you can start treatment sooner.
With a $12-million research grant from the National Institutes of Health, Cedars-Sinai is leading the way in cutting-edge studies on treatments and diagnostics for IPF and other serious lung conditions. Learn about clinical trials being conducted by our doctors and researchers.
Researchers and doctors at Cedars-Sinai have pioneered medical advances in lung care and remain at the forefront of innovative tests and treatments to improve patient outcomes. Learn more about our current pulmonary research.
Cedars-Sinai offers multiple options for graduate studies, postdoctoral research, continuing medical education and professional development in pulmonary and respiratory specialties.
When Paul Giordano was diagnosed with idiopathic pulmonary fibrosis (IPF), he thought he would have to get his affairs in order. But thanks to new medications prescribed by his Cedars-Sinai doctor, Paul W. Noble, MD, he now has renewed optimism—in fact, he and his wife just purchased a vacation home.